canertinib has been researched along with rociletinib in 3 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (rociletinib) | Trials (rociletinib) | Recent Studies (post-2010) (rociletinib) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 61 | 5 | 60 |
| Protein | Taxonomy | canertinib (IC50) | rociletinib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1682 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.1176 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.1057 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.072 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1176 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almaden, C; Bailey, S; Baxi, S; Behenna, D; Cheng, H; Cho-Schultz, S; Dalvie, D; Dinh, DM; Edwards, MP; Feng, JL; Ferre, RA; Gajiwala, KS; Hemkens, MD; Jackson-Fisher, A; Jalaie, M; Johnson, TO; Kania, RS; Kath, JC; Kephart, S; Lafontaine, J; Liu, KK; Liu, Z; Lunney, B; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Ornelas, MA; Orr, ST; Pairish, M; Planken, S; Ren, S; Richter, D; Ryan, K; Sach, N; Shen, H; Smeal, T; Solowiej, J; Sutton, S; Tran, K; Tseng, E; Vernier, W; Walls, M; Wang, S; Weinrich, SL; Xin, S; Xu, H; Yin, MJ; Zhou, R; Zientek, M | 1 |
| Almaden, C; Bailey, S; Ballard, TE; Behenna, DC; Bernier, L; Cheng, H; Cho-Schultz, S; Dalvie, D; Deal, JG; Dinh, DM; Edwards, MP; Ferre, RA; Gajiwala, KS; Hemkens, M; Johnson, TO; Kania, RS; Kath, JC; Lafontaine, J; Liu, L; Luo, Y; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Orr, ST; Pairish, M; Planken, S; Sach, NW; Shen, H; Shi, M; Solowiej, J; Tran, K; Tseng, E; Vicini, P; Wang, Y; Weinrich, SL; Xin, S; Zhang, C; Zhou, R; Zientek, M | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
3 other study(ies) available for canertinib and rociletinib
| Article | Year |
|---|---|
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Mutant Proteins; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants
Topics: Acrylamides; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dogs; Drug Design; ErbB Receptors; Halogenation; Humans; Lung; Lung Neoplasms; Mice; Models, Molecular; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Pyrrolidines; Rats | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |